Pay in 4 interest-free payments of $5.58 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
The proliferation of unauthorized manufacturers and online sellers can cause confusion among consumers, fuel market noise, and undermine trust in legitimate therapies
GLP-1s are considered safe and unprecedentedly effective aids to weight loss and associated health risks, such as type 2 diabetes
It has two mechanisms of action - both a GIP agonist and the GLP-1 agonist to work multiple pathways to aid in the potential to lose weight
It helps to minimise the impact of free radicals
There are three GLP-1 FDA decisions expected in early-mid 2026 Eli Lillys Mounjaro with a new indication to reduce the risk of major adverse cardiovascular events (MACE) in patients with T2DM Eli Lillys oral once-daily orforglipron for weight loss Novo Nordisks higher dose (7.2 mg) injectable once-weekly Wegovy for weight loss Given the considerable continued growth expected in the GLP-1 pipeline, Prime Therapeutics talented team of clinical experts actively monitors this emerging landscape
The conversation is no longer limited to prescription injections
